BIIB091
Based on 1 Customer Validation
BIIB091 is a potent, selective, orally active and reversible BTK inhibitor, with an IC50 of <0.5 nM. BIIB091 binds the BTK protein to sequester TYR-551 into an inactive conformation with excellent affinity. BIIB091 can be used for the research of multiple sclerosis.
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 2247614-80-6
- Formula: C28H34N10O2
- Molecular Weight:542.64
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B cell | IC50 |
71 nM
Compound: 51
|
Inhibition of CD69 (unknown origin) assessed as reduction in BCR mediated B cell activation
Inhibition of CD69 (unknown origin) assessed as reduction in BCR mediated B cell activation
|
[PMID: 34734694] |
| Monocyte | IC50 |
1.3 nM
Compound: 51
|
Inhibition of FcgammaRIII mediated TNF alpha secretion in anti-CD16 simulated human monocytes
Inhibition of FcgammaRIII mediated TNF alpha secretion in anti-CD16 simulated human monocytes
|
[PMID: 34734694] |
| Monocyte | IC50 |
3.1 nM
Compound: 51
|
Inhibition of FcgammaRI mediated TNF alpha secretion in anti-CD64 stimulated human monocyte
Inhibition of FcgammaRI mediated TNF alpha secretion in anti-CD64 stimulated human monocyte
|
[PMID: 34734694] |
| Monocyte | IC50 |
5.6 nM
Compound: 51
|
Inhibition of FcgammaR1 mediated TNF alpha secretion in IgG simulated human monocytes
Inhibition of FcgammaR1 mediated TNF alpha secretion in IgG simulated human monocytes
|
[PMID: 34734694] |
| Monocyte | IC50 |
5.6 nM
Compound: 51
|
Inhibition of FcgammaRIII mediated TNF alpha secretion in cross-linked anti-CD16 stimulated human monocyte
Inhibition of FcgammaRIII mediated TNF alpha secretion in cross-linked anti-CD16 stimulated human monocyte
|
[PMID: 34734694] |
| Monocyte | IC50 |
8 nM
Compound: 51
|
Inhibition of FcgammaRIII mediated TNF alpha secretion in anti-CD16 stimulated human monocyte
Inhibition of FcgammaRIII mediated TNF alpha secretion in anti-CD16 stimulated human monocyte
|
[PMID: 34734694] |
| Neutrophil | IC50 |
4.5 nM
Compound: 51
|
Inhibition of FcgammaR induced ROS production in human primary neutrophils
Inhibition of FcgammaR induced ROS production in human primary neutrophils
|
[PMID: 34734694] |
BIIB091 inhibits the phosphorylation of PLCγ2 in the Ramos human B-cell line, with an IC50 of 6.9 nM[1].
BIIB091 blocks anti-IgM-stimulated CD69 activation in PBMCs with an IC50 of 6.9 nM[1].
BIIB091 inhibits FcγR-induced ROS production in purified primary neutrophils, with an IC50 of 4.5 nM[1].
BIIB091 inhibits FcγRI and FcγRIII-mediated TNFα secretion upon simulation with FcγR agonists such as coated human IgG (all FcγR, IC50=5.6 nM), anti-CD16 (FcγRIII, IC50=8.0 nM), anti-CD64 (FcγRI IC50=3.1 nM), and cross-linked anti-CD16 (FcγRIII IC50=1.3 nM) in human monocytes[1].
BIIB091 inhibits the phosphorylation of BTK (IC50=24 nM) and blocks both BCR mediated B cell and FcεR-induced basophil activation as measured by inhibition of CD69 and CD63 expression (IC50=71 nM and IC50=82 nM, respectively) in the whole blood assays[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pharmacokinetics of BIIB091 in preclinical species[1]
| species | IV (1 mg/kg) | PO (5 mg/kg) in HMPC/Tween | |||||||
| T1/2 (h) | AUCinf (h•ng/mL) | CL (mL/min/kg) | CL %QH | Vdss (L/kg) | Tmax (h) | Cmax (ng/mL) | AUCinf (h•ng/mL) | %F | |
| rat | 2.1 | 748 | 10 | 22 | 0.4 | 0.9 | 693 | 1522 | 42 |
| cyno | 1.1 | 943 | 18 | 44 | 0.7 | 0.33 | 1104 | 1446 | 31 |
| dog | 6.0 | 1675 | 12 | 33 | 1.7 | 1.6 | 1440 | 6075 | 89 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice immunized with NP-Ficoll a thymus-independent type 2 (TI-2) antigen[1]
-
Dosage:0.03, 0.1, 0.3, 1, 10, 30 mg/kg in a CMC/Tween suspension formulation
-
Administration:P.o. twice daily for 10 days
-
Result:Observed a significant reduction of the anti-NP IgM antibody titers (88%, 77%, 59%, 59%, 44%, 34%, and 22%).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2247614-80-6
-
Appearance Solid
-
Molecular Weight 542.64
-
Formula C28H34N10O2
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CN(C(C)(C)C)N=N1)N[C@H]2C3=CC=C(C4=CC=NC(NC5=CN(C)N=C5)=N4)C=C3CN(C6COC6)CC2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 125 mg/mL (230.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8428 mL | 9.2142 mL | 18.4284 mL | 46.0711 mL |
| 5 mM | 0.3686 mL | 1.8428 mL | 3.6857 mL | 9.2142 mL | |
| 10 mM | 0.1843 mL | 0.9214 mL | 1.8428 mL | 4.6071 mL | |
| 15 mM | 0.1229 mL | 0.6143 mL | 1.2286 mL | 3.0714 mL | |
| 20 mM | 0.0921 mL | 0.4607 mL | 0.9214 mL | 2.3036 mL | |
| 25 mM | 0.0737 mL | 0.3686 mL | 0.7371 mL | 1.8428 mL | |
| 30 mM | 0.0614 mL | 0.3071 mL | 0.6143 mL | 1.5357 mL | |
| 40 mM | 0.0461 mL | 0.2304 mL | 0.4607 mL | 1.1518 mL | |
| 50 mM | 0.0369 mL | 0.1843 mL | 0.3686 mL | 0.9214 mL | |
| 60 mM | 0.0307 mL | 0.1536 mL | 0.3071 mL | 0.7679 mL | |
| 80 mM | 0.0230 mL | 0.1152 mL | 0.2304 mL | 0.5759 mL | |
| 100 mM | 0.0184 mL | 0.0921 mL | 0.1843 mL | 0.4607 mL |
Powered by Bioz